Sign in
TerminatedNo phase

LUNG INFECTION IN ICU (LUNG-I3)

Key facts

Who runs it
BioMérieux
Where
France1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
7 people enrolled
Started
5 Dec 2023
Ended
25 Jun 2026
Type of study
Observational
Record updated
30 October 2026
Why it stopped
Low recruitment

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • All the following criteria
  • Age 18 years or greater
  • Severe ICU patients hospitalized for one of the above diseases:; Septic shock (requirement of vasopressor to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol/L (>18 mg/dL) in the absence of hypovolemia) caused either by pneumonia (n=20) or another source n=20); Severe trauma (level I and II), Injury Severity Score ≥ 25 OR; Burn with TBSA over 20%
  • NAD > 0.1 µg/kg/min
  • At least 2 SOFA criteria ≥ 2 points

Who cannot take part

  • Immunocompromised patients, defined as; patients with solid tumors with chemotherapy in the last 3 months or a progressive metastatic disease; hematologic malignancies; solid organ transplantation; HIV infection with or without AIDS; treatment with corticosteroids (> 3 months at any dosage or ≥ 1 mg/kg prednisone equivalent per day for > 7 day); treatment with other immunosuppressive drugs
  • Aspiration pneumonia
  • Unable to obtain a valid and written consent from a patient or their legally authorized representative in accordance with the local regulatory instances (this includes in FR: Person not affiliated to a health insurance scheme, or not a beneficiary of such a scheme. Persons who are the subject of a legal protection order. Person with restricted freedom following a legal or administrative decision and a person admitted without their consent pursuant to Articles L.3212-1 and 3213-1, which are not included in Article L.1121-8 of the French Public Health Code.)
  • COPD
  • Smoke inhalation in burn patients
  • Participation in an intervention study
  • Pregnant or breastfeeding women

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

objective of LUNG-I3 study is to assess the quantitative and functional differences in cells between blood and bronchoalveolar lavage (BAL) fluid after an infection, with a special focus on alveolar macrophages and neutrophils

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
LUNG INFECTION IN ICU
Record updated
30 October 2026